Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AETHERA: Brentuximab vedotin post-ASCT for Hodgkin lymphoma
NCT01100502Phase 3Completed
- Sponsor
- Seagen Inc.
- Start
- Apr 2010
- Primary completion
- Aug 2014
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in Hodgkin lymphoma (HL) comparing Brentuximab vedotin with Placebo (2 arms). Primary endpoint: Progression-free Survival by Independent Review at 4 years. Started Apr 2010; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01100502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01100502.